MNKD
Undervalued by 18.1% based on the discounted cash flow analysis.
Market cap | $1.10 Billion |
---|---|
Enterprise Value | $1.18 Billion |
Dividend Yield | $0.0 (0.0%) |
Earnings per Share | $-0.04 |
Beta | 1.3 |
Outstanding Shares | 270,679,296 |
Avg 30 Day Volume | 2,525,095 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -92.51 |
---|---|
PEG | 85.81 |
Price to Sales | - |
Price to Book Ratio | -4.18 |
Enterprise Value to Revenue | 5.94 |
Enterprise Value to EBIT | 111.58 |
Enterprise Value to Net Income | -100 |
Total Debt to Enterprise | 0.32 |
Debt to Equity | -1.51 |
No data
No data
MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder,...